for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Peptidream Inc

4587.T

Latest Trade

5,090.00JPY

Change

-40.00(-0.78%)

Volume

370,700

Today's Range

5,030.00

 - 

5,100.00

52 Week Range

3,965.00

 - 

6,240.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
5,130.00
Open
5,100.00
Volume
370,700
3M AVG Volume
13.47
Today's High
5,100.00
Today's Low
5,030.00
52 Week High
6,240.00
52 Week Low
3,965.00
Shares Out (MIL)
125.17
Market Cap (MIL)
642,842.40
Forward P/E
182.21
Dividend (Yield %)
--

Next Event

Dividend For 4587.T - 0.0000 JPY

Latest Developments

More

PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical

PeptiDream says completion of technology transfer of Peptide Discovery Platform System to Shionogi

PeptiDream to invest 1.8 bln yen in peptide drugs unit

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Peptidream Inc

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

Industry

Biotechnology & Drugs

Contact Info

3-25-23, Tonomachi, Kawasaki-ku

+81.44.2701300

https://www.peptidream.com/

Executive Leadership

Kiichi Kubota

Chairman of the Board

Patrick Reid

President, Representative Director

Kiyofumi Kaneshiro

Vice President, Director

Keiichi Masuya

Vice President, Director

Yukinori Hanafusa

Independent Director

Key Stats

1.91 mean rating - 11 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
255.55
Price To Sales (TTM)
91.11
Price To Book (MRQ)
37.19
Price To Cash Flow (TTM)
209.73
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
15.83
Return on Equity (TTM)
14.79

Latest News

Latest News

Biotech-for-hire PeptiDream charts new path and becomes short target

The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target

The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

RPT-BRIEF-Shionogi & Co Ltd Announces Agreements On Collaborative Research With Peptidream For New Peptide Drug Conjugate(Pdc) Discovery

* SHIONOGI & CO LTD ANNOUNCES AGREEMENTS ON COLLABORATIVE RESEARCH WITH PEPTIDREAM INC FOR NEW PEPTIDE DRUG CONJUGATE (PDC) DISCOVERY Source text for Eikon: Further company coverage:

BRIEF-PeptiDream to invest 1.8 bln yen in peptide drugs unit

* Says it will invest 1.8 billion yen in Osaka-based peptide drugs unit

BRIEF-Peptidream announces discovery collaboration agreement with Bayer

* Peptidream announces discovery collaboration agreement with bayer

BRIEF-PeptiDream announces discovery collaboration agreement with Bayer AG

* Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG

BRIEF- PeptiDream announces change of chairman and president

* Says it appoints current president Kiichi Kubota as chairman of the board of the company

REFILE-TABLE-Peptidream-2016/17 parent results

Peptidream Inc. PARENT-ONLY FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Jun 30, 2017 Jun 30, 2016 Jun 30, 2018 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 4.90 4.33   more than 7.00 (+13.1...

BRIEF-PeptiDream to set up Osaka-based special peptide drugs JV

* Says it plans to set up Osaka-based joint venture with Shionogi & Co., Ltd and Sekisui Chemical Co., Ltd. , on Sept. 1

BRIEF- Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream

* Says its unit Heptares Therapeutics and PeptiDream Inc , a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with...

BRIEF- PeptiDream announces licensing of peptide discovery platform system (PDPS) technology to Shionogi

* Says it has entered into a technology license agreement with Osaka-based Shionogi & Co Ltd, to nonexclusively license PeptiDream’s proprietary Peptide discovery platform system (PDPS) technology

BRIEF-PeptiDream announces completion of technology transfer of Peptide Discovery Platform System to Lilly

* Says it completes the technology transfer of the Peptide Discovery Platform System (PDPS) to US-based Eli Lilly and Company

BRIEF-PeptiDream announces completion of technology transfer of Peptide Discovery Platform System to Genentech

* Says it completes the technology transfer of the Peptide Discovery Platform System (PDPS) to Genentech

BRIEF-PeptiDream enters into collaboration with Janssen Pharmaceuticals

* Says it entered into a multitarget discovery and optimization collaboration with Janssen Pharmaceuticals, inc, one of the Janssen Pharmaceutical Companies of Johnson & Johnson , on April 7

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up